The FDA (the U.S. Food and Drug Administration) has not approved the combination of sorafenib and radium-223 or the combination of pazopanib and radium-223 as a treatment for any disease. Sorafenib and pazopanib are both approved as single agents for the treatment of metastatic renal cell carcinoma. Additionally, radium-223 is FDA approved for the treatment of advanced prostate cancer and has shown to have effects on prostate cancer.